Announcements Trials
Browse Landscape

Phase

Phase 2 40Phase 3 28Phase 4 4Phase 1 4Phase NA 2Phase EARLY_PHASE1 2Phase 1/2 2Phase 2/3 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 4

Interventions

Dexamethasone 12Bevacizumab 9Saline Solution 8Bupivacaine 8Tobacco Use Cessation Devices 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 7Rituximab 6Prednisone 6Letrozole 6Lenalidomide 6Fluorouracil 6Cisplatin 6Carboplatin 6pembrolizumab 5Sodium Chloride 5Ropivacaine 5Human Papillomavirus Recombinant Vaccine nonavalent 5Trastuzumab 4Tamoxifen 4Standard of Care 4Propofol 4Paclitaxel 4Immune Checkpoint Inhibitors 4Esomeprazole 4Enoxaparin 4Doxorubicin 4Bortezomib 4Bismuth 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × Tamoxifen × 1 year × Clear all
NCT01127295 2026-04-14

PHACS

Institut Claudius Regaud

Phase 4 Completed
2,000 enrolled
Breast

Breast Neoplasms

NCT01553903 2026-04-14

OXYTAM

Institut Claudius Regaud

Phase 4 Completed
29 enrolled
Breast

Breast Neoplasms

NCT01612871 2026-04-14

MIRHO

Institut Claudius Regaud

Phase 4 Completed
39 enrolled
Breast

Breast Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Novartis

Phase 4 Active not recruiting
134 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡